Demagraft

Advances in Wound Care,  Nov/Dec 1999  by Thomas, Cathy

• E-mail
• Print
• Link

Data also presented at the European Tissue Repair Society meeting indicated that Dermagraft, a bioengineered skin substitute from Advanced Tissue Sciences, Inc, and Smith & Nephew, stimulates angiogenesis, both in diabetic foot ulcers patients and in the laboratory.

Blood flow increased 75% (P

According to the researchers, the improvement in blood flow-as measured by laser Doppler imaging-may reflect angiogenesis in the healing wound, possibly enhanced by a sustained and appropriate supply of angiogenic growth factors provided by Dermagraft.

In addition, scientists from the Wound Healing Research Unit, University of Wales College of Medicine, Cardiff, Wales, presented data showing that release of vascular endothelial cadherin and beta catenin was enhanced in human vascular endothelial cells co-cultured with Dermagraft. These proteins are believed to be important in angiogenesis.

Dermagraft, a bioengineered skin substitute intended to treat certain diabetic foot ulcers, is currently available in Canada and Europe. Food and Drug Administration approval is pending in the United States. Tolterodine

Research presented at the combined International Continence Society 29th Annual Meeting and the International Urogynecologic Association 24th Annual Meeting indicated that tolterodine (Detrol) not only reduces incontinence episodes by 50% in patients with overactive bladder, but it also is well tolerated for long-term treatment.

Tolterodine, recently introduced in the United States for management of overactive bladder, is marketed by Pharmacia and Upjohn.

Copyright Springhouse Corporation Nov/Dec 1999
Provided by ProQuest Information and Learning Company. All rights Reserved